Sio Capital Management, LLC has revealed a substantial investment in Enveric Biosciences, Inc., according to a recent filing. The firm disclosed ownership of 330,000 shares, which accounts for 7.37% of Enveric's total shares outstanding. This development is noteworthy as it reflects Sio Capital's growing influence in the pharmaceutical preparations sector.

Enveric Biosciences is a company focused on developing and commercializing innovative therapies for patients with cancer and other serious conditions. The filing indicates that Sio Capital's investment is made on behalf of certain affiliated funds that hold shares for their investors. This strategic move may enhance Sio Capital's position within the competitive landscape of the pharmaceutical industry.

Background

Sio Capital Management, LLC is a Delaware-based investment adviser that specializes in managing funds. The firm has been active in the market, with multiple filings indicating its investment strategies. The recent filing, dated November 3, 2026, is a Schedule 13G, which is used to report beneficial ownership of securities.

What the Filing Says

In the filing, Sio Capital reported that it beneficially owns 330,000 shares of Enveric Biosciences, giving it shared voting and dispositive power over these shares. The filing states, "As of September 30, 2026, Sio Capital Management, LLC beneficially owned 330,000 shares of Common Stock with shared voting power and shared dispositive power." This ownership is based on Enveric's disclosure of 4,475,884 shares outstanding as of August 12, 2026.

Impact

This investment may affect various stakeholders, including Enveric Biosciences, its shareholders, and competitors in the pharmaceutical sector. As Sio Capital increases its stake, it may influence corporate governance and strategic decisions at Enveric. The filing also highlights the role of investment advisers like Sio in shaping the future of companies within the pharmaceutical preparations industry.

What's Next

The filing does not indicate what happens next regarding Sio Capital's investment strategy or any potential actions concerning their stake in Enveric Biosciences.